Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Reporting Period: Second Quarter ended June 28, 2015
Date of Report: July 21, 2015
This filing provides supplemental information regarding the Company's Q2 2015 financial results, including clarifications on instrument shipments, consumable revenue trends, and order metrics.
Key Financial Metrics and Operational Data
- Sequencing Consumable Revenue: Approximately $250 million for Q2 2015, representing a sequential increase.
- Book-to-Bill Ratio: 1.1 for Q2 2015, described as a notable increase versus typical trends.
- Instrument Utilization:
- HiSeq X and NextSeq: Utilization per instrument exceeded guidance ranges.
- MiSeq and HiSeq: Utilization per instrument remained within guidance ranges.
- Annual Utilization Guidance (per instrument):
- MiSeq: $40K - $45K
- NextSeq: $80K - $100K
- HiSeq: $300K - $350K
- HiSeq X: $600K - $650K
Material Changes and Clarifications
- HiSeq Shipments: Total shipments of HiSeq models (2500, 3000, and 4000), excluding HiSeq X, increased both year-over-year and sequentially.
- HiSeq X Shipments: Shipments of HiSeq X instruments were lower sequentially and year-over-year. The filing clarifies that a previous statement inadvertently omitted the "X" qualifier.
- Consumables Mix: The sequential increase in sequencing consumable revenue was offset by a greater decline in array consumables.
- Order Rate Definition: The expected normalized quarterly order rate for HiSeq X refers to 20 to 30 units, not systems. (Note: A HiSeq X Five system comprises five units; a HiSeq X Ten system comprises ten units).
Guidance, Outlook, and Management Commentary
- Franchise Health: Management characterized the sequencing consumables franchise as "very robust."
- Order Strength: Q2 was described as a "strong order quarter."
- Performance vs. Expectations: Sequencing consumables exceeded expectations in the quarter, driven by high utilization on HiSeq X and NextSeq platforms.
- Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the operational clarifications provided.
Investor Verification Checklist
- Verify the distinction between HiSeq X units versus systems when analyzing order rate guidance (20-30 units).
- Confirm the divergence in performance between sequencing consumables (up sequentially) and array consumables (down sequentially).
- Review the specific shipment trends for HiSeq X (down) versus other HiSeq models (up) to understand the product mix shift.
- Assess the sustainability of the 1.1 book-to-bill ratio compared to historical trends.